The matter will come up again in court on Monday
HAL can make up to 50 per cent of bulk drugs if it is provided financial assistance to upgrade its infrastructure, the company said
Despite having good demand from across the markets, primarily due to lower prices and easy availability, India controls only 2.4 per cent of global pharma exports
Trivitron Healthcare currently has nine manufacturing facilities across five locations -- Chennai, Mumbai, Pune, Ankara and Helsinki
The company has filed an application before the directorate for investigation into the imports from these countries for imposing anti-dumping duty
The product is being recalled due to a label error on declared strength
CoC says parent firm has no assets other than holding in Orchid Pharma, which itself is undergoing CIRP; Even if there is a resolution for Orchid Pharma, nothing would be left for investors
The products are manufactured either in the plant owned by KRRP in China, or partners in China, or in India by Dr. Reddy's
Dr Reddy's was in the news for falling short of expectations during routine audits conducted by the US drug regulator
Concerns over US sales are diluting positives of strong domestic growth, and have led to a 10 per cent fall in the Nifty Pharma index in one month
The Telangana unit in question is an important one contributing about a fifth to US revenues
Have increased raw material buffer stock by at least 40 days in recent months
Front end of the business to go to a separate firm, which will focus on achieving Rs 10,000 cr revenue and 30% ROCE within 5 years
As per the state FDCA commissioner, the state has benefited from the introduction of GST
The completion of Sandoz acquisition and new product launches are triggers
Besides captive consumption, the company also supplies APIs to external customers across international markets
In India, the company said it will focus on therapeutic segments like diabetes, dermatology, cardiology and women's health
According to Edelweiss Securities, pharma sales to grow by 17 per cent YoY as US sales are expected to grow by 21 per cent YoY
The idea is to cancel the licenses of manufacturers who do not deposit the demanded amount within the prescribed time limit given by the NPPA
Those with high non-US revenue streams such as Torrent Pharma, Ipca Labs, Ajanta Pharma and a few multinationals remain well placed